

**Publishing options in a Hybrid journal:  
Poland institute associated authors**

**Program A: publikacje finansowane z licencji krajowej  
aktualizacja 25.10.2021**



# Key information

## 1. How do we determine eligibility of the article for the Poland agreement?

- The submission date of the article should be on or after 1st January 2019
  - 2019 submissions receive a discount of 30% and 2020 submission receive for 20% discount on the APC
  - 2021 submissions receive full APC coverage\*
- The corresponding author must be from a participating Polish institute
- The article must be from a participating journal

\*UWAGA: po wykorzystaniu puli programu A 2021 oferowany jest 10% discount

# Key information

## 2. Why do we use submission date as the eligibility criteria?

- The submission date is the only stable point in the publishing process. Acceptance and publication dates vary based on the journal processes
- The author controls the submission date. This gives the author not only control, but also transparency and predictability, regardless of how long the review and publication process takes



## Finalize Publishing your Article

**Corresponding author receives an email post acceptance with a link a unique link to complete the author journey and choose publishing options**

**Author clicks on Complete the Rights and Access information form**

### Demo: Dummy article title



Corresponding author	Dr. Lee Chahin
E-mail address	leechahin@cphuniv.com
Journal	Accident Analysis and Prevention
Our reference	AAP989
PII	S0001-4575(21)00097-X

#### Welcome Dr. Chahin,

To help us finalize the publication of your article please complete the publishing form(s) below.

**Note:** you will receive a confirmation e-mail after completing each form.

When placing orders via these forms, you may be asked to provide the information listed below.

- **Purchase Order Number**  
If a Purchase Order Number is required for payment by your institution and you already have one, please provide it via the publishing form(s). Note that you may still complete the form(s) now, even if you do not have the Purchase Order number available yet.
- **Tax Exemption Number and Tax Exemption Certificate** if applicable to your institution.

For Bank and company address details, see the [Information you may need to supply to complete the options](#).

## Rights and Access

[Complete the Rights and Access information form](#)

Elsevier supports responsible sharing. To find out how you can share your article, please visit our [Sharing Policy page](#).

For information on author rights visit Elsevier's [Author Rights](#) pages.

For information on publishing open access with Elsevier visit [elsevier.com/openaccess](https://elsevier.com/openaccess).

# Rights and Access



**Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Poland agreement**

Demo: Dummy article title

Corresponding author	Dr. Lee Chahin
E-mail address	leechahin@cphuniv.com
Journal	Accident Analysis and Prevention
Our reference	AAP989
PII	S0001-4575(21)00097-X

### Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

- Organization name\*
- Warsaw University of Life Sciences
  - Warsaw University of Life Sciences**
  - Warszawa, PL
  - Warsaw University of Life Sciences Department of Plant Physiology
  - Warszawa, PL
  - Warsaw University of Life Sciences, Department of Pathology and Veterinary Diagnostics
  - Warszawa, PL
  - Warsaw University of Life Sciences Main Library
  - Warszawa, PL
  - Warsaw University of Life Sciences, Institute of Biology, Department of Plant Physiology
  - Warszawa, PL

Save and Continue >

Copyright ©  
Cookies are:

[Conditions](#) [Privacy Policy](#) [Cookie Notice](#) [Contact us](#)

1

Corresponding Author

2

Co-Author

3

Research Funders

4

Publishing Options

5

Review Order

6

Confirmation

**Corresponding author also adds the co-author affiliation details**

Demo: Dummy article title

Were there any co-authors for this article?

Yes

No

## Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial\*

John

Last name\*

Head

Organization name\*

KU Leuven


Or use recently selected organization

Warsaw University of Life Sciences +

+ Add another co-author

Previous

Save and Continue >



**Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case Milliman, United States is the Funder**

Demo: Dummy article title ▼

Did the research in this article receive funding?

Yes

No

### Funder Details ?

To help us determine the best publishing options for your article, please provide details of the organization(s) that funded the research. For tips on searching for an organization please visit our [Support Center](#).

If providing details for two or more organizations, please list the organization(s) that provided the most funding first, as this will help us determine the publishing options for your article.

**Organization name\*** 🗑️

Milliman Inc

**Grant/Contract numbers\*** 🗑️

GT123

[+ Add grant/contract number](#)

[+ Add another organization](#)

Previous

Save and Continue >

- Based on the affiliation details, the author sees the Publishing Options. Gold OA option is followed by Subscription option\* and we make it clear that agreement covers full APC

**\*UWAGA: opcja subskrypcji pojawia się jedynie w przypadku czasopism HYBRYDOWYCH**

- If the librarian at the institution rejects the author request in the Elsevier Portal, we also make it clear that the authors will receive a full price invoice and in case of no funding, the author can change the option to subscription\*\*

**\*\*UWAGA: opcja zmiany typu publikacji pojawia się JEDYNIEM w przypadku czasopism HYBRYDOWYCH; w przypadku czasopism Open Access autor NIE MA możliwości uniknięcia opłaty APC**

- Author selects OA

Based on information you have provided, your publishing options are shown below


## Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with a Polish institution, the agreement between Elsevier and Gold Open Access Pilot national program in Poland will cover the APC according to the [rules of the Open Access pilot program in Poland](#).

I and others can share and reuse my article in the ways described by the user license I select.

 Your institution prefers you to publish Gold OA

### Article Publishing Charge (APC)

Price  
EUR 3000.00

Institutional Agreement Discount



- 3,000.00

To pay (on validation)



0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,000.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Poland \(ICM\) and Elsevier Agreement.](#)

## Subscription

Publish as a subscription article

Make my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#).


I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article [sharing rights outlined here](#).

Previous

Save and Continue >



## Rights and Access



In case of OA, author selects the CC License

**UWAGA: jest to wybór autora, ale zwracamy uwagę, że licencja CC-BY jest wymagana w Planie S, którego sygnatariuszem jest m.in. NCN**

Demo: Dummy article title

### Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

CC BY 4.0

A license to permit readers to share and adapt your article for any purpose, even commercially.

[Read more about CC BY 4.0](#)

CC BY-NC-ND 4.0

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

[Read more about CC BY-NC-ND 4.0](#)

Previous

Save and Continue >

## Author selects the Rights

Demo: Dummy article title

Elsevier B.V.

### Select Your Status

- I am the sole author of the manuscript
  - I am one author signing on behalf of all co-authors of the manuscript
- Please indicate which of the below applies to you:
- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
  - I am a US Government employee but some of my co-authors are not
  - I am not a US Government employee but some of my co-authors are
  - The work was performed by contractors of the US Government under contract number:
- Contract Number\*
- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
  - Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
  - None of the above
  - I am signing as an authorized representative and on behalf of my employer

### Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.


I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)\*

E-mail address\*

Previous

Save and Continue >



Demo: Dummy article title

Elsevier B.V.

## Your Status

- I am one author signing on behalf of all co-authors of the manuscript

## License of Publishing Rights

I hereby grant to Elsevier B.V. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

## Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

## Research Data

## License agreement page

## Author agrees with the terms of license agreement

I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure and information for authors from countries affected by sanctions (Iran, Cuba, or Syria). Please note that some journals may require that all co-authors sign and submit Declarations of Interest disclosure forms. I am also aware of the publisher's policies with respect to retractions and withdrawal (<https://www.elsevier.com/about/our-business/policies/article-withdrawal>).

For further information see the publishing ethics page at <https://www.elsevier.com/about/our-business/policies/publishing-ethics> and the journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions>

### Author representations


- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.

I have read and agree to the terms of the License Agreement.



- This is the summary page explaining the choices the author made in the publishing journey
- Corresponding author and coauthors receive a copy of summary via email
- Article becomes OA on ScienceDirect within 24 hours
- Librarian receives a notification to validate the APC request within 48 hours who then has 3 weeks to validate the request

Demo: Dummy article title

## Review Order

Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none"><li>• I am one author signing on behalf of all co-authors of the manuscript</li></ul> <p>I may share my final published article widely in accordance with the <a href="#">user License</a> that I have selected.</p> <p>Further details on <a href="#">Elsevier Sharing Policy here</a>.</p>

21 June 2021

Previous

## Total payment due

Price (excluding taxes)

**EUR 3000.00**

Institutional Agreement Discount



**- 3,000.00**

To pay (on validation)



**0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,000.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Poland \(ICM\) and Elsevier Agreement.](#)

Finish >

**Publishing author journey videos:**

[https://service.elsevier.com/app/answers/detail/a\\_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP\\_X/](https://service.elsevier.com/app/answers/detail/a_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP_X/)

**Author questions:** [support@elsevier.com](mailto:support@elsevier.com)

**Librarian questions:** [agreementactivation@elsevier.com](mailto:agreementactivation@elsevier.com)

Thank you

